AstraZeneca Pharma India Limited — Important, 10-02-2025: Updates

AstraZeneca Pharma India Limited has received a warning letter from the National Stock Exchange regarding a compliance issue. The warning pertains to the company's Audit Committee meeting held on May 27, 2024, where only one independent director attended, failing to meet the quorum requirements outlined in Regulation 18(2)(b) of the SEBI Listing Regulations. The exchange emphasized that this non-compliance is taken seriously and advised the company to implement corrective measures to prevent recurrence. Importantly, the letter notes that the financial impact of this warning is negligible. Stakeholders should monitor how the company addresses this compliance issue to ensure governance practices are reinforced, presenting both risks and opportunities for future performance.